nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Oily skin—Octreotide—thymus cancer	0.152	0.152	CcSEcCtD
Naltrexone—Pancreatitis acute—Octreotide—thymus cancer	0.0274	0.0274	CcSEcCtD
Naltrexone—Appetite absent—Octreotide—thymus cancer	0.0254	0.0254	CcSEcCtD
Naltrexone—Loose stools—Octreotide—thymus cancer	0.0228	0.0228	CcSEcCtD
Naltrexone—Pregnancy—Octreotide—thymus cancer	0.0223	0.0223	CcSEcCtD
Naltrexone—Haemorrhoids—Octreotide—thymus cancer	0.0215	0.0215	CcSEcCtD
Naltrexone—Cholelithiasis—Octreotide—thymus cancer	0.0203	0.0203	CcSEcCtD
Naltrexone—Abdominal cramps—Octreotide—thymus cancer	0.0187	0.0187	CcSEcCtD
Naltrexone—Paranoia—Octreotide—thymus cancer	0.0185	0.0185	CcSEcCtD
Naltrexone—Seborrhoeic dermatitis—Octreotide—thymus cancer	0.0185	0.0185	CcSEcCtD
Naltrexone—Throat sore—Octreotide—thymus cancer	0.0175	0.0175	CcSEcCtD
Naltrexone—Oropharyngeal discomfort—Octreotide—thymus cancer	0.0174	0.0174	CcSEcCtD
Naltrexone—Injection site pain—Octreotide—thymus cancer	0.0155	0.0155	CcSEcCtD
Naltrexone—Oropharyngeal pain—Octreotide—thymus cancer	0.0139	0.0139	CcSEcCtD
Naltrexone—Cellulitis—Octreotide—thymus cancer	0.0139	0.0139	CcSEcCtD
Naltrexone—Muscle twitching—Octreotide—thymus cancer	0.0129	0.0129	CcSEcCtD
Naltrexone—Injection site reaction—Octreotide—thymus cancer	0.0126	0.0126	CcSEcCtD
Naltrexone—Hyperkinesia—Octreotide—thymus cancer	0.011	0.011	CcSEcCtD
Naltrexone—Phlebitis—Octreotide—thymus cancer	0.0106	0.0106	CcSEcCtD
Naltrexone—Sleep disorder—Octreotide—thymus cancer	0.0106	0.0106	CcSEcCtD
Naltrexone—Gastroenteritis—Octreotide—thymus cancer	0.0103	0.0103	CcSEcCtD
Naltrexone—Cardiac failure congestive—Octreotide—thymus cancer	0.0101	0.0101	CcSEcCtD
Naltrexone—Nasal congestion—Octreotide—thymus cancer	0.0101	0.0101	CcSEcCtD
Naltrexone—Hot flush—Octreotide—thymus cancer	0.0098	0.0098	CcSEcCtD
Naltrexone—Menopausal symptoms—Octreotide—thymus cancer	0.00971	0.00971	CcSEcCtD
Naltrexone—Arthritis—Octreotide—thymus cancer	0.00943	0.00943	CcSEcCtD
Naltrexone—Pain in extremity—Octreotide—thymus cancer	0.00917	0.00917	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00917	0.00917	CcSEcCtD
Naltrexone—Psychotic disorder—Octreotide—thymus cancer	0.00895	0.00895	CcSEcCtD
Naltrexone—Irritability—Octreotide—thymus cancer	0.00875	0.00875	CcSEcCtD
Naltrexone—Dehydration—Octreotide—thymus cancer	0.00852	0.00852	CcSEcCtD
Naltrexone—Abdominal pain upper—Octreotide—thymus cancer	0.00837	0.00837	CcSEcCtD
Naltrexone—Cramp muscle—Octreotide—thymus cancer	0.00825	0.00825	CcSEcCtD
Naltrexone—Nasopharyngitis—Octreotide—thymus cancer	0.0082	0.0082	CcSEcCtD
Naltrexone—Influenza—Octreotide—thymus cancer	0.00792	0.00792	CcSEcCtD
Naltrexone—Sweating increased—Octreotide—thymus cancer	0.00772	0.00772	CcSEcCtD
Naltrexone—Bronchitis—Octreotide—thymus cancer	0.00762	0.00762	CcSEcCtD
Naltrexone—Abdominal discomfort—Octreotide—thymus cancer	0.0076	0.0076	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Octreotide—thymus cancer	0.00736	0.00736	CcSEcCtD
Naltrexone—Weight increased—Octreotide—thymus cancer	0.00721	0.00721	CcSEcCtD
Naltrexone—Weight decreased—Octreotide—thymus cancer	0.00717	0.00717	CcSEcCtD
Naltrexone—Pneumonia—Octreotide—thymus cancer	0.00711	0.00711	CcSEcCtD
Naltrexone—Depression—Octreotide—thymus cancer	0.00704	0.00704	CcSEcCtD
Naltrexone—Urinary tract infection—Octreotide—thymus cancer	0.00687	0.00687	CcSEcCtD
Naltrexone—Conjunctivitis—Octreotide—thymus cancer	0.00687	0.00687	CcSEcCtD
Naltrexone—Hepatobiliary disease—Octreotide—thymus cancer	0.00668	0.00668	CcSEcCtD
Naltrexone—Epistaxis—Octreotide—thymus cancer	0.00666	0.00666	CcSEcCtD
Naltrexone—Sinusitis—Octreotide—thymus cancer	0.00663	0.00663	CcSEcCtD
Naltrexone—Hepatitis—Octreotide—thymus cancer	0.00634	0.00634	CcSEcCtD
Naltrexone—Pharyngitis—Octreotide—thymus cancer	0.00629	0.00629	CcSEcCtD
Naltrexone—Tinnitus—Octreotide—thymus cancer	0.00591	0.00591	CcSEcCtD
Naltrexone—Cardiac disorder—Octreotide—thymus cancer	0.00589	0.00589	CcSEcCtD
Naltrexone—Immune system disorder—Octreotide—thymus cancer	0.00573	0.00573	CcSEcCtD
Naltrexone—Alopecia—Octreotide—thymus cancer	0.0056	0.0056	CcSEcCtD
Naltrexone—Mental disorder—Octreotide—thymus cancer	0.00556	0.00556	CcSEcCtD
Naltrexone—Malnutrition—Octreotide—thymus cancer	0.00552	0.00552	CcSEcCtD
Naltrexone—Flatulence—Octreotide—thymus cancer	0.00544	0.00544	CcSEcCtD
Naltrexone—Tension—Octreotide—thymus cancer	0.00542	0.00542	CcSEcCtD
Naltrexone—Nervousness—Octreotide—thymus cancer	0.00536	0.00536	CcSEcCtD
Naltrexone—Back pain—Octreotide—thymus cancer	0.00534	0.00534	CcSEcCtD
Naltrexone—Muscle spasms—Octreotide—thymus cancer	0.00531	0.00531	CcSEcCtD
Naltrexone—Vision blurred—Octreotide—thymus cancer	0.0052	0.0052	CcSEcCtD
Naltrexone—Tremor—Octreotide—thymus cancer	0.00517	0.00517	CcSEcCtD
Naltrexone—Ill-defined disorder—Octreotide—thymus cancer	0.00512	0.00512	CcSEcCtD
Naltrexone—Agitation—Octreotide—thymus cancer	0.00507	0.00507	CcSEcCtD
Naltrexone—Malaise—Octreotide—thymus cancer	0.00498	0.00498	CcSEcCtD
Naltrexone—Syncope—Octreotide—thymus cancer	0.00495	0.00495	CcSEcCtD
Naltrexone—Palpitations—Octreotide—thymus cancer	0.00488	0.00488	CcSEcCtD
Naltrexone—Loss of consciousness—Octreotide—thymus cancer	0.00485	0.00485	CcSEcCtD
Naltrexone—Cough—Octreotide—thymus cancer	0.00482	0.00482	CcSEcCtD
Naltrexone—Convulsion—Octreotide—thymus cancer	0.00478	0.00478	CcSEcCtD
Naltrexone—Hypertension—Octreotide—thymus cancer	0.00477	0.00477	CcSEcCtD
Naltrexone—Arthralgia—Octreotide—thymus cancer	0.0047	0.0047	CcSEcCtD
Naltrexone—Chest pain—Octreotide—thymus cancer	0.0047	0.0047	CcSEcCtD
Naltrexone—Myalgia—Octreotide—thymus cancer	0.0047	0.0047	CcSEcCtD
Naltrexone—Anxiety—Octreotide—thymus cancer	0.00468	0.00468	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00467	0.00467	CcSEcCtD
Naltrexone—Discomfort—Octreotide—thymus cancer	0.00464	0.00464	CcSEcCtD
Naltrexone—Dry mouth—Octreotide—thymus cancer	0.0046	0.0046	CcSEcCtD
Naltrexone—Anaphylactic shock—Octreotide—thymus cancer	0.00451	0.00451	CcSEcCtD
Naltrexone—Oedema—Octreotide—thymus cancer	0.00451	0.00451	CcSEcCtD
Naltrexone—Infection—Octreotide—thymus cancer	0.00448	0.00448	CcSEcCtD
Naltrexone—Shock—Octreotide—thymus cancer	0.00443	0.00443	CcSEcCtD
Naltrexone—Nervous system disorder—Octreotide—thymus cancer	0.00442	0.00442	CcSEcCtD
Naltrexone—Tachycardia—Octreotide—thymus cancer	0.0044	0.0044	CcSEcCtD
Naltrexone—Skin disorder—Octreotide—thymus cancer	0.00438	0.00438	CcSEcCtD
Naltrexone—Hyperhidrosis—Octreotide—thymus cancer	0.00436	0.00436	CcSEcCtD
Naltrexone—Anorexia—Octreotide—thymus cancer	0.00429	0.00429	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Octreotide—thymus cancer	0.0041	0.0041	CcSEcCtD
Naltrexone—Insomnia—Octreotide—thymus cancer	0.00407	0.00407	CcSEcCtD
Naltrexone—Paraesthesia—Octreotide—thymus cancer	0.00405	0.00405	CcSEcCtD
Naltrexone—Dyspnoea—Octreotide—thymus cancer	0.00402	0.00402	CcSEcCtD
Naltrexone—Somnolence—Octreotide—thymus cancer	0.00401	0.00401	CcSEcCtD
Naltrexone—Decreased appetite—Octreotide—thymus cancer	0.00392	0.00392	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Octreotide—thymus cancer	0.00389	0.00389	CcSEcCtD
Naltrexone—Fatigue—Octreotide—thymus cancer	0.00388	0.00388	CcSEcCtD
Naltrexone—Constipation—Octreotide—thymus cancer	0.00385	0.00385	CcSEcCtD
Naltrexone—Pain—Octreotide—thymus cancer	0.00385	0.00385	CcSEcCtD
Naltrexone—Feeling abnormal—Octreotide—thymus cancer	0.00371	0.00371	CcSEcCtD
Naltrexone—Gastrointestinal pain—Octreotide—thymus cancer	0.00368	0.00368	CcSEcCtD
Naltrexone—Urticaria—Octreotide—thymus cancer	0.00358	0.00358	CcSEcCtD
Naltrexone—Body temperature increased—Octreotide—thymus cancer	0.00356	0.00356	CcSEcCtD
Naltrexone—Abdominal pain—Octreotide—thymus cancer	0.00356	0.00356	CcSEcCtD
Naltrexone—Hypersensitivity—Octreotide—thymus cancer	0.00332	0.00332	CcSEcCtD
Naltrexone—Asthenia—Octreotide—thymus cancer	0.00323	0.00323	CcSEcCtD
Naltrexone—Pruritus—Octreotide—thymus cancer	0.00319	0.00319	CcSEcCtD
Naltrexone—Diarrhoea—Octreotide—thymus cancer	0.00308	0.00308	CcSEcCtD
Naltrexone—Dizziness—Octreotide—thymus cancer	0.00298	0.00298	CcSEcCtD
Naltrexone—Vomiting—Octreotide—thymus cancer	0.00286	0.00286	CcSEcCtD
Naltrexone—Rash—Octreotide—thymus cancer	0.00284	0.00284	CcSEcCtD
Naltrexone—Dermatitis—Octreotide—thymus cancer	0.00284	0.00284	CcSEcCtD
Naltrexone—Headache—Octreotide—thymus cancer	0.00282	0.00282	CcSEcCtD
Naltrexone—Nausea—Octreotide—thymus cancer	0.00268	0.00268	CcSEcCtD
